Clinical Trials Browser

Not yet recruiting × Glioblastoma × tislelizumab × Clear all

NCT05540275 2023-10-06

Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

Phase 2 Not yet recruiting

Glioblastoma

NCT05502991 2022-09-27

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma

Phase 2 Not yet recruiting

Glioblastoma